Sign in
4

Changes in Ownership

Denali Therapeutics Inc. Filed Acc 0001714899-23-000066

President and CEO sold 25,000 shares at an average $25.15 ($628,720)

  • President and CEO acquired 25,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Watts Ryan J. · President and CEO

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2023-04-20 Exercise or conversion : show line 1 in the form +200 $0.68 $136 2,240,113 I
2023-04-20 Sale : show line 2 in the form −200 $25.00 $5,000 2,239,913 I
2023-04-21 Exercise or conversion : show line 3 in the form +24,800 $0.68 $16,864 2,264,713 I
2023-04-21 Sale : show line 4 in the form −24,800 $25.15 $623,720 2,239,913 I
Open-market sales · 25,000 sh · avg $25.15 · $628,720

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2023-04-20 Exercise or conversion : show line 5 in the form Stock Option (right to buy) −200 1,195,417 D
2023-04-21 Exercise or conversion : show line 6 in the form Stock Option (right to buy) −24,800 1,170,617 D
Loading xslF345X04/wf-form4_168237782624985.xml…